Key Takeaway
Clinical data suggests retatrutide produces significantly more weight loss than Ozempic. Compare efficacy, mechanisms, side effects, and what the data actually shows.
Clinical data suggests retatrutide produces significantly more weight loss than Ozempic (semaglutide), with trial participants losing an average of 28.7% of body weight compared to approximately 15% with semaglutide at its highest approved dose. That's nearly double the weight loss, which is a striking difference by any clinical standard. But "better" depends on more than just a single number, and the full comparison requires looking at mechanisms, side effects, availability, and long-term data.
A key limitation: retatrutide and semaglutide have never been tested head-to-head in a clinical trial. The numbers we're comparing come from separate studies with different patient populations, protocols, and timeframes. But the gap is large enough that most researchers and clinicians expect the difference to hold up even in a direct comparison.
The Weight Loss Numbers
In the Phase 2 trial published in the New England Journal of Medicine in 2023, participants taking the highest dose of retatrutide (12mg weekly) lost an average of 28.7% of their body weight over 48 weeks. For context, that translates to roughly 71 pounds for a person starting at 248 pounds, which was close to the average baseline weight in the study.
By comparison, semaglutide 2.4mg (the dose used in Wegovy, the weight loss formulation of the same drug in Ozempic) produced average weight loss of about 15% of body weight over 68 weeks in the STEP 1 trial[1]. Ozempic itself, which is approved for type 2 diabetes at a maximum dose of 2mg, typically produces weight loss in the range of 10-12%.
So whether you compare retatrutide to Ozempic specifically or to the higher-dose Wegovy formulation, retatrutide comes out well ahead on the weight loss metric.
Why the Difference? The Triple Agonist Mechanism
The primary reason retatrutide outperforms semaglutide is its mechanism of action. Ozempic works on a single hormone receptor: GLP-1. Retatrutide works on three receptors simultaneously: GLP-1, GIP, and glucagon. For a complete cost breakdown, see our compare GLP-1 providers.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Placebo | 2 | ~2% weight loss |
| 4 mg | 17 | ~17% at 48 weeks |
| 8 mg | 22 | ~22% at 48 weeks |
| 12 mg | 24 | ~24% at 48 weeks |
Each of these receptors contributes to weight loss through different pathways:
- GLP-1: Reduces appetite, slows gastric emptying, and improves insulin sensitivity. This is the mechanism Ozempic relies on exclusively.
- GIP: Works together effectively with GLP-1 to enhance satiety signals and improve metabolic function. This is the second target in tirzepatide (Mounjaro/Zepbound).
- Glucagon: Increases energy expenditure by boosting the body's metabolic rate and promoting fat breakdown. This is the receptor unique to retatrutide among current obesity drugs.
The glucagon component is particularly significant. While GLP-1 and GIP primarily work by reducing calorie intake (you eat less because you feel full sooner), glucagon increases the number of calories your body burns at rest. This dual approach of eating less and burning more creates a compounding effect that explains the superior weight loss results.
Side Effect Comparison
Both retatrutide and Ozempic share a common side effect profile rooted in their GLP-1 activity. Gastrointestinal symptoms are the most frequently reported issues with both drugs. These include nausea, vomiting, diarrhea, and constipation.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →In retatrutide's Phase 2 trial, gastrointestinal side effects were reported by a majority of participants, particularly during the dose escalation phase. Nausea was the most common complaint, reported by approximately 45% of participants on the highest dose. Most of these symptoms were mild to moderate and decreased over time as the body adjusted.
Ozempic has a well-documented side effect profile after years of real-world use. Nausea affects roughly 20-30% of users, and the overall tolerability is considered acceptable by most prescribers. The drug has also been associated with rare but serious concerns including pancreatitis, gallbladder disease, and thyroid C-cell tumors in animal studies.
Because retatrutide adds glucagon receptor activity to the mix, there's a theoretical concern about effects on blood sugar in non-diabetic patients (glucagon raises blood sugar) and potential liver effects. The Phase 2 data did not reveal alarming signals in these areas, but Phase 3 trials with larger patient populations will provide a clearer picture.
Until retatrutide completes its full trial program and accumulates real-world data, Ozempic has a significant safety advantage simply because we know more about it. Ozempic has been prescribed to millions of patients worldwide since its approval in 2017. That depth of experience can't be replicated by clinical trial data alone.
Availability and Practical Considerations
Ozempic is available right now. You can get a prescription from your doctor today, fill it at your local pharmacy, and start treatment this week. Retatrutide is still in Phase 3 trials and is likely two or more years away from FDA approval.
This isn't a trivial distinction. For someone dealing with obesity-related health complications right now, waiting years for a theoretically better drug isn't always the right choice. Starting treatment with an available medication and transitioning to retatrutide later, if appropriate, may be a more practical strategy.
Cost is another consideration. Ozempic currently lists at around $900 per month before insurance, though many patients pay significantly less with coverage or manufacturer savings programs. Retatrutide's pricing hasn't been announced, but analysts expect it to launch at a premium given its superior efficacy data.
Key Points
On pure weight loss performance, retatrutide appears to be substantially better than Ozempic. The clinical data shows nearly twice the weight reduction, driven by a more thorough mechanism that targets three hormone pathways instead of one.
But "better" in medicine is rarely one-dimensional. Ozempic has years of real-world safety data, broad insurance coverage, established prescribing protocols, and immediate availability. Retatrutide has none of these things yet.
For patients making treatment decisions today, Ozempic and its weight loss counterpart Wegovy remain excellent, proven options. For patients who can wait, retatrutide represents what could be a significant leap forward in obesity pharmacotherapy. The smart approach is to work with your doctor, start with what is available and effective now, and keep an eye on retatrutide as it moves through the approval process.
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]